Robert Gibson - Scopus Biopharma S Chairman
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Insider
Robert Gibson is S Chairman of Scopus Biopharma
| Phone | 212 479 2513 |
| Web | https://scopusbiopharma.com |
Scopus Biopharma Management Efficiency
The company has return on total asset (ROA) of (4.6089) % which means that it has lost $4.6089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.596) %, meaning that it created substantial loss on money invested by shareholders. Scopus Biopharma's management efficiency ratios could be used to measure how well Scopus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| David MD | Erasca Inc | 40 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Antony CPA | Forte Biosciences | 57 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| Jonathan MD | Erasca Inc | 52 | |
| CPA MS | Erasca Inc | 55 | |
| Hannah Fry | Protara Therapeutics | 33 | |
| Andrew MBA | Monopar Therapeutics | 52 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| MBA MPH | Protara Therapeutics | 41 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Wei MD | Erasca Inc | 54 | |
Management Performance
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 |
Scopus Biopharma Leadership Team
Elected by the shareholders, the Scopus Biopharma's board of directors comprises two types of representatives: Scopus Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scopus. The board's role is to monitor Scopus Biopharma's management team and ensure that shareholders' interests are well served. Scopus Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scopus Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ira Greenspan, Advisor Director | ||
| David Silberg, Advisor | ||
| Robert Gibson, S Chairman | ||
| Alan Horsager, PresofImmunoOncology BioTherapeutics |
Scopus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Scopus Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Shares Owned By Insiders | 50.66 % | ||||
| Shares Owned By Institutions | 2.15 % | ||||
| Number Of Shares Shorted | 23.77 K | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (26.95 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |